UTHealth Houston has secured millions in grant funding — plus has reached a new milestone for one of its projects. Photo via utsystem.edu

UTHealth Houston is making waves in many disciplines right now. From cancer to Alzheimer’s disease to stroke, the institution is improving outcomes for patients in new ways. Last week, UTHealth announced three exciting updates to its roster of accomplishments.

On October 8, UTHealth announced that it had received a $4.8 million grant from the National Cancer Institute, aimed at helping cancer survivors to continue their healing and enhancing primary care capacity. It will be put into action by UTHealth researchers working with eight community health centers around Texas that treat un- and underinsured patients. The initiative is called Project CASCADE, which stands for Community and Academic Synergy for Cancer Survivorship Care Delivery Enhancement.

“Project CASCADE focuses on how primary healthcare teams provide whole-person and coordinated care to underserved patients who have a history of cancer,” says Bijal Balasubramanian, professor of epidemiology and the Rockwell Distinguished Chair in Society and Health at UTHealth Houston School of Public Health, a multiple principal investigator of the study. “Primary care is uniquely suited to deliver whole-person and coordinated care for cancer survivors because, at its core, it prioritizes, personalizes and integrates healthcare for all conditions, not just the cancer.”

She continued by adding that 70 percent of cancer survivors live with other chronic conditions. The study will help by taking a holistic approach, rather than relegating people’s care to many different teams. Project CASCADE is one of only four National Cancer Institute-funded U01 grants that have been awarded to applicants focused on primary care for cancer survivors.

“Community health centers are the primary-care homes for patients who are underinsured or uninsured. In collaboration with community health center clinics, this study will develop a model of cancer survivorship care that can be disseminated and scaled up to be used across other health systems in Texas,” Balasubramanian says.

The intervention will use a designated care coordinator champion to oversee every aspect of patients’ health journey. Project ECHO will provide a backbone for treatment. That’s a telementoring strategy that improves primary care clinicians’ knowledge about post-cancer care, recognition and management of the effects of cancer and its treatments, and communication between oncologists and the primary care team. Project CASCADE is also a partnership between The University of Texas System institutions, including UT Southwestern Medical Center and The University of Texas MD Anderson Cancer Center.

The previous week, UTHealth made history by performing the first infusion in Houston of a newly FDA-approved drug, Kisunla, for the treatment of early symptomatic Alzheimer’s disease. The lucky recipient was 79-year-old Terrie Frankel. Though Kisunla is not a cure for Alzheimer’s, it has been noted to slow progress when administered early in the disease’s encroachment.

“Mrs. Frankel is the ideal patient for this treatment,” her doctor, David Hunter says. “We want to see patients as soon as they, or their family, notice the slightest trace of forgetfulness. The earlier the patient is in their Alzheimer’s disease, the more they benefit from treatments like Kisunla.”

UTHealth was one of the sites in the trial that charted the fact that Kisunla reduced amyloid plaques on average by 84 percent at 10 months after infusion. Frankel will receive her infusions monthly for the next 18 months, and her doctors will keep tabs on her progress with PET scans and use MRIs to scan for possible side effects. Next year, researchers will begin recruiting participants over the age of 55 with a family history of dementia, but no memory loss themselves, for a new trial, one of several currently working against Alzheimer’s that are taking place at UTHealth.

Stroke is no less of a worry to many patients. Last week, UTHealth received another grant that will improve the odds for patients who have had a stroke with the successful re-opening of a blocked vessel through endovascular surgery. The $2.5 million grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, will fund a five-year study that will include the creation of a machine-learning program that will be able to predict which stroke patients with large blood vessel blockages will benefit most from endovascular therapy.

The investigators will form a database of imaging and outcomes of patients whose blockages were successfully opened, called reperfusion, from three U.S. hospitals. This will allow them to identify clinical and imaging-based predictors of damage in the brain after reperfusion. From there, the deep-learning model will help clinicians to know which patients might go against the tenet that the sooner you treat a patient, the better.

“This is shaking our core of deciding who we treat, and when, and how, but also, how we are evaluating them? Our current methods of determining benefit with imaging are not good enough,” says principal investigator and associate professor in the Department of Neurology at McGovern Medical School at UTHealth Houston, Sunil Sheth.

And this is just some of the groundbreaking work taking place at UTHealth each day.

A medical device designed by a UH professor will close the loop with high frequency brain waves to prevent seizures from occurring. Photo via uh.edu

University of Houston engineer receives $3.7M to work on seizure-preventing tech

brainy med device

A professor at the University of Houston has received a federal grant aimed at helping stop epileptic seizures before they start.

The BRAIN Initiative at the National Institute of Neurological Disorders and Stroke awarded the $3.7 million grant to Nuri Firat Ince, an associate professor of biomedical engineering at UH. The grant will go toward Ince's work to create a seizure-halting device based on his research.

According to UH, Ince has reduced by weeks the time it takes to locate the seizure onset zone (SOZ), the part of the brain that causes seizures in patients with epilepsy. He's done this by detecting high-frequency oscillations (HFO) forming "repetitive waveform patterns" that identify their location in the SOZ.

Ince plans to use those HFOs to help control seizures. But he first must determine whether the HFOs can be detected with an implantable closed-loop device, enabling delivery of electrical stimulation that can control seizures. The device is called a brain interchange system. A closed-loop system supplies stimulation only when it detects the onset of a seizure.

Ince's neurotechnology partner, Cortec GMBH of Freiburg, Germany, is supplying the brain interchange system. Houston's Baylor College of Medicine eventually will be the site where medical professionals implant the device in pediatric and adult epilepsy patients.

"If the outcomes of our research in acute settings become successful, we will execute a clinical trial and run our methods with the implanted … system in a chronic ambulatory setting," Ince says in a UH news release.

Research published recently in the journal AJOB Neuroscience found that a closed-loop brain implant being used to treat refractory epilepsy does not alter patients' personalities or self-perception.

Nuri Firat Ince associate professor of biomedical engineering. Photo via uh.edu

"Next-generation brain stimulation devices can modulate brain activity without human intervention, which raises new ethical and policy questions," lead author Tobias Haeusermann of the University of California, San Francisco, says in a news release. "But while there is a great deal of speculation about the potential consequences of these innovative treatments, very little is currently known about patients' experiences of any device approved for clinical use."

The study, however, found no evidence that the device Haeusermann and his colleagues studied had changed patients' personalities or self-perception.

Haeusermann and his fellow researchers based their study on a closed-loop device that's currently available. In 2013, the U.S. Food and Drug Administration (FDA) approved this brain stimulation system for treatment of refractory epilepsy. It's the first clinically approved and commercially available closed-loop brain stimulation device for epilepsy patients. Refractory epilepsy occurs when medication no longer controls seizures.

According to a research article published in 2018, epilepsy ranks among the most common neurological disorders, affecting about 1% of the global population. For patients who suffer seizures that cannot be treated with drugs, a frequent treatment is surgical removal of the SOZ.

In this country, about 3 million adults and 470,000 children have epilepsy, according to the U.S. Centers for Disease Control and Prevention, including nearly 293,000 Texans. In the U.S., epilepsy is the fourth most common neurological disorder, preceded by migraine, stroke and Alzheimer's disease, the Epilepsy Foundation of Michigan says.

About 150,000 Americans are diagnosed each year with epilepsy.

Epilepsy is prevalent among people with autism, cerebral palsy, Down syndrome, and intellectual disabilities.

About 30 types of seizure occur among the more than 60 types of epilepsy, the Michigan foundation says. A seizure briefly disturbs electrical activity in the braining, causing temporary changes in movement, awareness, feelings, behavior, and other bodily functions.

Daily medication is the standard treatment for epilepsy, according to the Michigan foundation. Still, 30 percent to 40 percent of people with epilepsy continue to experience seizures.

Each year, U.S. health care costs associated with epilepsy add up to roughly $28 billion, according to the American Journal of Managed Care.

"Most people with epilepsy are able to lead productive and fulfilling lives, but for many, epilepsy can be a devastating condition," the foundation says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.